Rockwell Medical (FRA:RWMA) EBIT: €-3.68 Mil (TTM As of Mar. 2026)


FRA:RWMA Rockwell Medical Inc FRA:RWMA
30 GF Score
Price €0.59
GF Value €0.75
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Rockwell Medical EBIT?

Rockwell Medical FRA:RWMA +0.86% 30 EBIT is €-3.68 Mil as of Mar. 2026. GuruFocus rates FRA:RWMA with a GF Score™ of 30/100 and a GF Value™ of €0.75 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Rockwell Medical's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-1.14 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-3.68 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Rockwell Medical's annualized ROC % for the quarter that ended in Mar. 2026 was -20.97%. Rockwell Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -37.10%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Rockwell Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -24.18%.


Rockwell Medical  (FRA:RWMA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Rockwell Medical's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-5.12 * ( 1 - 0% )/( (24.3 + 24.523)/ 2 )
=-5.12/24.4115
=-20.97 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Rockwell Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-4.576/( ( (6.703 + max(4.675, 0)) + (8.205 + max(5.084, 0)) )/ 2 )
=-4.576/( ( 11.378 + 13.289 )/ 2 )
=-4.576/12.3335
=-37.10 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.954 + 2.924 + 1.366) - (3.155 + 1.158 + 2.256)
=4.675

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7.634 + 2.643 + 1.014) - (4.483 + 0.493 + 1.231)
=5.084

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Rockwell Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-3.678/15.214
=-24.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rockwell Medical EBIT Related Terms


Rockwell Medical EBIT Historical Data

* Premium members only.

The historical data trend for Rockwell Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rockwell Medical EBIT Chart

Rockwell Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.83 -15.81 -5.63 0.74 -3.58

Rockwell Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.15 -1.05 -1.25 -0.23 -1.14

FRA:RWMA vs MRMD, CPHI, HYEX: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rockwell Medical EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Rockwell Medical's EV-to-EBIT falls into.


FRA:RWMA
30GF Score
Rockwell Medical Inc FRA:RWMA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rockwell Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-3.68 Mil mean?
Rockwell Medical (FRA:RWMA) has a EBIT of €-3.68 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Rockwell Medical.
Is Rockwell Medical's EBIT too high?
Rockwell Medical's current EBIT is €-3.68 Mil. Overall, Rockwell Medical has a GF Score™ of 30/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's EBIT compare to MRMD and CPHI?
Rockwell Medical's EBIT of €-3.68 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Rockwell Medical. Rockwell Medical's current EBIT is €-3.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (FRA:RWMA) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.75, compared to a current price of €0.59 — trading 22% below its estimated fair value. The current EBIT is €-3.68 Mil. Rockwell Medical's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Rockwell Medical (FRA:RWMA), the current EBIT is €-3.68 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rockwell Medical (FRA:RWMA) Overvalued in 2026?

Based on GuruFocus' analysis, Rockwell Medical stock appears to be undervalued. The current stock price of €0.59 is trading 22% below its estimated GF Value™ of €0.75. GuruFocus considers Rockwell Medical to be Modestly Undervalued.

Key valuation signals for FRA:RWMA:

  • EBIT: €-3.68 Mil
  • GF Value™: €0.75 vs. price of €0.59 (22% below fair value)
  • GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the FRA:RWMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rockwell Medical Business Description

Other Exchanges RMTI:USA
Address 30142 South Wixom Road, Wixom, MI, USA, 48393
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
30GF Score

Get the complete analysis for FRA:RWMA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.59
Price
€0.75
GF Value